APA (7th ed.) Citation

JY, C., SH, L., W, D., Z, L., SJ, G., CM, G., . . . JV, H. (2023). Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial. Lancet (London, England), 402(10405), 871. https://doi.org/10.1016/S0140-6736(23)01384-3

Chicago Style (17th ed.) Citation

JY, Chang, et al. "Stereotactic Ablative Radiotherapy with or Without Immunotherapy for Early-stage or Isolated Lung Parenchymal Recurrent Node-negative Non-small-cell Lung Cancer: An Open-label, Randomised, Phase 2 Trial." Lancet (London, England) 402, no. 10405 (2023): 871. https://doi.org/10.1016/S0140-6736(23)01384-3.

MLA (9th ed.) Citation

JY, Chang, et al. "Stereotactic Ablative Radiotherapy with or Without Immunotherapy for Early-stage or Isolated Lung Parenchymal Recurrent Node-negative Non-small-cell Lung Cancer: An Open-label, Randomised, Phase 2 Trial." Lancet (London, England), vol. 402, no. 10405, 2023, p. 871, https://doi.org/10.1016/S0140-6736(23)01384-3.